Fig. 3.

Comparison of the effects of various patient characteristics on the selection of DPP-4i or metformin as the first-line OAD by specialists (a; DPP-4 n = 118, metformin n = 107) and nonspecialists (b; DPP-4 n = 148, metformin n = 85). The values shown in the figure are the percentages of physicians who considered the patient characteristics when selecting a DPP-4i or metformin as the first-line OAD. BMI body mass index, CV cardiovascular, DPP-4i dipeptidyl peptidase-4 inhibitor, FPG fasting plasma glucose, OAD oral antidiabetes drug, PPG postprandial glucose